Back to dashboard
CommercialCoverageLow impact

08.00.64h, Natalizumab (Tysabri®) and Related Biosimilars

Independence Blue Cross·Neurology·Pharmacy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

The Natalizumab (Tysabri®) and Related Biosimilars pharmacy policy has been reissued with updates effective April 2, 2025. This policy governs coverage and authorization requirements for this specialty multiple sclerosis medication and its biosimilar alternatives.

Action Required

Action needed
By April 2, 2025: Billing team should review the updated Natalizumab policy at the provided URL to identify any changes in prior authorization requirements, coverage criteria, or billing procedures for Tysabri and related biosimilars. Update any relevant billing protocols based on policy changes discovered.

Related policy hubs